Patients with undetectable hsTnI levels (<2 ng/L) were at statistically significantly lower risk (adjusted HR, 0.42; 95% CI, 0.26-0.68; P < .001) of the primary end point, and patients with hsTnI levels exceeding 6 ng/L were at 2-fold higher risk (adjusted HR, 2.03; 95% CI, 1.71-2.41; P < .001). All-cause mortality is shown rather than CV death because there were no CV deaths in patients with hsTnI levels less than 2 ng/L, precluding calculation of an HR.